ReviewCancers2022
Endocrine Late Effects in Childhood Cancer Survivors.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Long-term outcomes of pediatric medulloblastoma before routine molecular classification: a 20-year single-center cohort study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Epigenome-wide analysis identifies DNA methylation mediators of treatment-related cardiometabolic risk in survivors of childhood cancer.Nature communications · 2026Article
- Fertility preservation and subsequent reproductive outcomes in female pediatric patients with hematologic malignancies.Frontiers in endocrinology · 2026Review
- Microvascular skeletal muscle oxygenation and exercise capacity in childhood cancer survivors compared to healthy controls: a cross-sectional study.Scientific reports · 2025Article
- Article
- Adolescent Survivors of Childhood Cancer: Biopsychosocial Challenges and the Transition from Survival to Quality of Life.Children (Basel, Switzerland) · 2025Review
- Early Endocrine and Metabolic Complications in Childhood Cancer Survivors-Experience from a Tertiary Care Pediatric Oncology Center in South India.South Asian journal of cancer · 2025Article
- Suicide Ideation, Attempt and Mortality in Childhood Cancer Survivors a Scoping Review of the Literature.Psycho-oncology · 2025Article
- Correlation of FSTL1 and its paralogs with body composition in adult survivors of childhood cancer.Scientific reports · 2025Article
- Cancer survivorship in low- and middle-income countries: challenges, needs, and emerging support strategies.Frontiers in public health · 2025Review
- EndoCompass Project: Research Roadmap for Endocrine Causes and Consequences of Cancers.Hormone research in paediatrics · 2025Review
- Late Complications in Long-Term Childhood Cancer Survivors: What the Oral Health Professional Needs to Know.Dentistry journal · 2024Review
- Causal associations between site-specific cancer and diabetes risk: A two-sample Mendelian randomization study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood cancer management has improved considerably over the years, leading to a significant improvement in survival of up to 80%. However, childhood cancer survivors are at the highest risk of developing sequelae resulting from treatment, with endocrine complications being frequently observed among survivors. Multiple predisposing factors for endocrine sequelae have been identified, including age at diagnosis, treatment received, radiation, tumor type, and genetic polymorphisms, which could explain the individual predisposition to develop drug toxicity. Novel agents targeting tumor growth and immune checkpoint inhibitors have recently become the cornerstone for the treatment of different cancers, triggering a myriad of immune-related endocrinopathies. Endocrine sequelae of cancer therapy will have an impact on not only childhood but also on the survival and quality of life of these highly complex patients. Therefore, lifelong monitoring of childhood cancer survivors at risk of endocrine diseases is paramount. Encouraging oncologists and endocrinologists to develop new follow-up and early detection guidelines that minimize sequelae among these patients has become a priority, promoting integration between pediatric and adult units since many sequelae may manifest only after years to decades of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.